The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation.
作者： Dwaine F. Emerich , Reginald L. Dean , Chester Osborn , Raymond T. Bartus
DOI: 10.2165/00003088-200140020-00003
关键词: Receptor 、 Distribution (pharmacology) 、 Medicine 、 In vivo 、 Blood–brain barrier 、 Peptide 、 Bradykinin 、 Internal medicine 、 Endocrinology 、 Permeability (electromagnetism) 、 Agonist
摘要: Labradimil (Cereport®; also formerly referred to as RMP-7) is a 9-amino-acid peptide designed for selectivity the bradykinin B2 receptor and longer plasma half-life than bradykinin. It has been developed increase permeability of blood-brain barrier (BBB) first compound with selective agonist properties progress from concept design through tests efficacy in patients.
springer.com
sci-hub.se 参考文章(71)
Dwaine F Emerich, Reginald L Dean, JoAnne Marsh, Melissa Pink, Denise Lafreniere, Pamela Snodgrass, Raymond T Bartus, Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Pharmaceutical Research. ,vol. 17, pp. 1212- 1219 ,(2000) , 10.1023/A:1026462629438
Julie Ann Straub, Alan Akiyama, Parul Parmar, In vitro plasma metabolism of RMP-7. Pharmaceutical Research. ,vol. 11, pp. 1673- 1676 ,(1994) , 10.1023/A:1018986510570
John R. Fike, Glenn T. Gobbel, Ali H. Mesiwala, Hyung J. Shin, Minoru Nakagawa, Kathleen R. Lamborn, Theresa M. Seilhan, Peter J. Elliott, Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain. Journal of Neuro-oncology. ,vol. 37, pp. 199- 215 ,(1998) , 10.1023/A:1005874206814
W. Boogerd, J.J. van der Sande, N. van Zandwijk, Teniposide sometimes effective in brain metastases from non-small cell lung cancer. Journal of Neuro-oncology. ,vol. 41, pp. 285- 289 ,(1999) , 10.1023/A:1006168507111
Malcolm B. Segal, Hugh Davson, Physiology of the CSF and Blood-Brain Barriers ,(1996)
Jerry Frankenheim, Roger M. Brown, Bioavailability of drugs to the brain and the blood-brain barrier U.S. Dept. of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse , For sale by the U.S. G.P.O., Supt. of Docs.. ,(1992)
A. Gregor, M. Lind, H. Newman, R. Grant, D.M. Hadley, T. Barton, C. Osborn, Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma Journal of Neuro-oncology. ,vol. 44, pp. 137- 145 ,(1999) , 10.1023/A:1006379332212
C D Strader, R W Ransom, T MacNeil, A W Derrick, J G Menke, J A Borkowski, K K Bierilo, J F Hess, D L Linemeyer, K A Schneck, Expression cloning of a human B1 bradykinin receptor. Journal of Biological Chemistry. ,vol. 269, pp. 21583- 21586 ,(1994) , 10.1016/S0021-9258(17)31844-6
M. Gary I. Riley, Norman N. Kim, Vance E. Watson, Y. Pierre Gobin, Carl P. LeBel, Keith L. Black, Raymond T. Bartus, Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: A toxicologic evaluation in swine Journal of Neuro-oncology. ,vol. 36, pp. 167- 178 ,(1998) , 10.1023/A:1005751922174
Keiro Ikeda, Tomotsugu Ichikawa, Hiroaki Wakimoto, Jonathan S. Silver, Thomas S. Deisboeck, Dianne Finkelstein, Griffith R. Harsh, David N. Louis, Raymond T. Bartus, Fred H. Hochberg, E. Antonio Chiocca, Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses Nature Medicine. ,vol. 5, pp. 881- 887 ,(1999) , 10.1038/11320